{"product_id":"baylor-college-of-medicine-3rd-annual-opioid-use-disorder-conference-2025","title":"Baylor College of Medicine 3rd Annual Opioid Use Disorder Conference 2025","description":"\u003ch1 class=\"product_title entry-title\"\u003eBaylor College of Medicine 3rd Annual Opioid Use Disorder Conference 2025\u003c\/h1\u003e\r\n\u003cstrong\u003e Include: 12 videos + 12 audios + 12 file sub vtts, size: 4.96 GB\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eTarget Audience: physicians and advanced-practice providers in psychiatry, emergency medicine, family medicine, internal medicine, and obstetrics and gynecology\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eInformation:\u003c\/strong\u003e\r\n\u003cdiv class=\"field-label\"\u003eCourse opens: \u003cstrong\u003eFriday, April 11, 2025 \u003c\/strong\u003e\n\u003c\/div\u003e\r\nThe opioid use epidemic has been at the forefront of societal concerns in the United States. The DEA-MATE act requires all providers to adeptly prescribe and manage Opioid Use Disorder (OUD) and related issues. Treating teams face multiple challenges, including treating chronic pain, preventing over-prescription of opioids, and addressing illicit use. This conference will provide education on evidence-based treatment techniques, including pharmacologic and psychotherapeutic approaches, to manage OUD. Attendees will learn to recognize barriers to accessing medication, apply person-first language, and identify signs and symptoms of opioid use disorder and withdrawal. Additionally, attendees will gain knowledge on how to refer patients to appropriate resources for outpatient care, ultimately empowering them to initiate and\/or maintain effective treatments for OUD with confidence.\r\n\u003ch4\u003eTARGET AUDIENCE\u003c\/h4\u003e\r\nThis activity is for physicians and advanced-practice providers in psychiatry, emergency medicine, family medicine, internal medicine, and obstetrics and gynecology and the community.\r\n\u003ch4\u003eEDUCATIONAL OBJECTIVES\u003c\/h4\u003e\r\nAt the conclusion of this activity, the participants should be able to:\r\n\u003cul\u003e\r\n \t\u003cli\u003eApply treatment techniques, including pharmacologic and psychotherapeutic approaches, in managing Opioid Use Disorder.\u003c\/li\u003e\r\n \t\u003cli\u003eRecognize barriers to accessing medication in treatment of Opioid Use Disorder treatment.\u003c\/li\u003e\r\n \t\u003cli\u003eRecall and apply person first language, emphasizing the individual rather than the diagnosis, when interacting with patients diagnosed with Opioid Use Disorder.\u003c\/li\u003e\r\n \t\u003cli\u003eIdentify and appropriately respond to signs and symptoms of opioid use disorder and opioid withdrawal.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n \r\n\r\n\u003cstrong\u003e Topics:\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e01 A System Lens on Treating Patients with Substance Use Disorders\u003c\/li\u003e\r\n \t\u003cli\u003e02 To Eliminate Hepatitis C, Treat Those Who Inject Drugs\u003c\/li\u003e\r\n \t\u003cli\u003e03 Center for Behavioral Emergency and Addiction Research (CBEAR)\u003c\/li\u003e\r\n \t\u003cli\u003e04 Managing Opioid Withdrawal in the Emergency Department – ED-Initiated Buprenorphine\u003c\/li\u003e\r\n \t\u003cli\u003e05 What do Buprenorphine Levels Really Tell Us Quantitative Analyses in Relation to Clinical Response\u003c\/li\u003e\r\n \t\u003cli\u003e06 Co-Occurring Stimulant and Opioid Use Disorders, A Clinical Challenge\u003c\/li\u003e\r\n \t\u003cli\u003e07 Technology Advances in Substance Use Treatment\u003c\/li\u003e\r\n \t\u003cli\u003e08 Expansion of Medications for Opioid Use Disorder in Correctional Facilities\u003c\/li\u003e\r\n \t\u003cli\u003e09 Community-Based, Specialized SUD Treatment for Women and Families\u003c\/li\u003e\r\n \t\u003cli\u003e10 ADHD, Opioids, and the Family – Protecting Vulnerable Youth\u003c\/li\u003e\r\n \t\u003cli\u003e11 Implementation of a Tobacco-Free Workplace Program in Opioid Treatment Centers in Texas – Findings and Future Directions\u003c\/li\u003e\r\n \t\u003cli\u003e12 The Pharmacology of CNS Depressant Polypharmacy That is Bringing Us Down\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv id=\"block-yui_3_17_2_1_1727871960836_2124\" class=\"markdown-block sqs-block sqs-block-markdown\" data-block-type=\"44\"\u003e\u003c\/div\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":42954527178850,"sku":"MED-AMB05358","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/005a2678-7b4e-4482-b22d-aefd6e7e5840.png?v=1779378946","url":"https:\/\/meducourse.com\/products\/baylor-college-of-medicine-3rd-annual-opioid-use-disorder-conference-2025","provider":"Meducourse","version":"1.0","type":"link"}